JPMorgan analyst Richard Vosser raised the firm’s price target on Novartis to CHF 92 from CHF 85 and keeps a Neutral rating on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Novartis announces positive opinion for Cosentyx in hidradenitis suppurativa
- Novartis to present Kisqali Phase III NATALEE trial data at ASCO
- Bristol-Myers adds new U.S. manufacturing facility for viral vector production
- Novartis announces results from Phase III APPOINT-PNH trial of iptacopan
- Novartis upgraded to Buy from Hold at Deutsche Bank
